Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589720 | 0.85 | CYP3A4 (0.41) | MEN1KMT2ACYP3A4CYP2C9P2RY2 | |
| SCHEMBL22589644 | 0.80 | DHFR (0.38) | MEN1KMT2ADUTCYP3A4CYP2C9 | |
| SCHEMBL24625563 | 0.79 | MEN1 (0.37) | MEN1KMT2ADUTCYP3A4CYP2C9 | |
| SCHEMBL21178144 | 0.72 | LMNA (0.45) | — | |
| SCHEMBL22589418 | 0.72 | LMNA (0.38) | — | |
| SCHEMBL22801265 | 0.71 | LMNA (0.41) | RNASE1 | |
| SCHEMBL22801237 | 0.71 | LMNA (0.43) | — | |
| SCHEMBL22801224 | 0.70 | LMNA (0.39) | — | |
| SCHEMBL21179053 | 0.69 | LMNA (0.41) | — | |
| SCHEMBL21178974 | 0.69 | LMNA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220145-A1 | CYCLIC PHOSPHATE COMPOUNDS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-07-14 | — | — | US | disclosed |
| WO-2020219464-A1 | CYCLIC PHOSPHATE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220145-A1 | CYCLIC PHOSPHATE COMPOUNDS | PYGL, ALPP, PHPT1 | MEN1 3120/4885KMT2A 4805/4885DUT 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.